WO2014089149A8 - Procédé de traitement d'une maladie associée à une espèce oligomère soluble d'amyloïde bêta 1-42 - Google Patents

Procédé de traitement d'une maladie associée à une espèce oligomère soluble d'amyloïde bêta 1-42 Download PDF

Info

Publication number
WO2014089149A8
WO2014089149A8 PCT/US2013/072991 US2013072991W WO2014089149A8 WO 2014089149 A8 WO2014089149 A8 WO 2014089149A8 US 2013072991 W US2013072991 W US 2013072991W WO 2014089149 A8 WO2014089149 A8 WO 2014089149A8
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid beta
treating
disease associated
soluble
oligomeric species
Prior art date
Application number
PCT/US2013/072991
Other languages
English (en)
Other versions
WO2014089149A1 (fr
Inventor
William F GOURE
Franz F. Hefti
Renee C. GASPAR
Paul J. SHUGHRUE
Fubao Wang
Weirong Wang
Ningyan Zhang
Wei-Qin Zhao
Original Assignee
Acumen Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. filed Critical Acumen Pharmaceuticals, Inc.
Priority to AU2013355359A priority Critical patent/AU2013355359B2/en
Priority to EP13859810.7A priority patent/EP2928561A4/fr
Priority to US14/648,316 priority patent/US20150320860A1/en
Priority to CA2891627A priority patent/CA2891627C/fr
Priority to JP2015545800A priority patent/JP6731727B2/ja
Publication of WO2014089149A1 publication Critical patent/WO2014089149A1/fr
Publication of WO2014089149A8 publication Critical patent/WO2014089149A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne un procédé et un kit pour traiter une maladie associée à, ou due à, l'accumulation d'amyloïde bêta 1-42 oligomère soluble, au moyen d'un anticorps, ou d'un fragment de cet anticorps, qui présente une affinité pour les oligomères d'amyloïde bêta 1-42 plus élevée que pour le monomère d'amyloïde bêta 1-42, le monomère d'amyloïde bêta 1-40, les plaques et les fibrilles d'amyloïde bêta, l'anticorps étant en combinaison avec une substance thérapeutique ciblé sur Tau ou un inhibiteur de la production ou de l'agrégation d'amyloïde bêta.
PCT/US2013/072991 2012-12-04 2013-12-04 Procédé de traitement d'une maladie associée à une espèce oligomère soluble d'amyloïde bêta 1-42 WO2014089149A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2013355359A AU2013355359B2 (en) 2012-12-04 2013-12-04 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP13859810.7A EP2928561A4 (fr) 2012-12-04 2013-12-04 Procédé de traitement d'une maladie associée à une espèce oligomère soluble d'amyloïde bêta 1-42
US14/648,316 US20150320860A1 (en) 2012-12-04 2013-12-04 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
CA2891627A CA2891627C (fr) 2012-12-04 2013-12-04 Procede de traitement d'une maladie associee a une espece oligomere soluble d'amyloide beta 1-42
JP2015545800A JP6731727B2 (ja) 2012-12-04 2013-12-04 アミロイドベータ１−４２の可溶性オリゴマー種に関連する疾患を治療するための方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/693,362 2012-12-04
US13/693,362 US9320793B2 (en) 2010-07-14 2012-12-04 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Publications (2)

Publication Number Publication Date
WO2014089149A1 WO2014089149A1 (fr) 2014-06-12
WO2014089149A8 true WO2014089149A8 (fr) 2015-05-14

Family

ID=50883986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/072991 WO2014089149A1 (fr) 2012-12-04 2013-12-04 Procédé de traitement d'une maladie associée à une espèce oligomère soluble d'amyloïde bêta 1-42

Country Status (6)

Country Link
US (2) US9320793B2 (fr)
EP (1) EP2928561A4 (fr)
JP (2) JP6731727B2 (fr)
AU (1) AU2013355359B2 (fr)
CA (1) CA2891627C (fr)
WO (1) WO2014089149A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101831459B1 (ko) 2010-03-03 2018-04-04 더 유니버시티 오브 브리티시 콜롬비아 올리고머 특이적 아밀로이드 베타 에피토프 및 항체
EP2732286A4 (fr) * 2011-07-13 2015-02-25 Merck Sharp & Dohme Procédé de détection d'oligomères bêta-amyloïdes dans un échantillon liquide et ses utilisations
WO2018031361A2 (fr) * 2016-08-09 2018-02-15 Eli Lilly And Company Polythérapie
BR112020021728A2 (pt) 2018-04-27 2021-01-26 Shionogi & Co., Ltd. derivados de tetra-hidropiranooxazina tendo atividade inibitória de bace1 seletiva
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
WO2024086796A1 (fr) 2022-10-20 2024-04-25 Alector Llc Anticorps anti-ms4a4a avec des thérapies à base d'amyloïdes-bêta

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2572602A1 (fr) 2004-07-02 2006-02-09 Northwestern University Anticorps monoclonaux ciblant des ensembles pathologiques d'amyloides .beta. (abeta)
KR20070040824A (ko) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
WO2007050359A2 (fr) 2005-10-21 2007-05-03 Merck & Co., Inc. Anticorps monoclonal anti-addl et leur utilisation
JP2008520589A (ja) * 2004-11-17 2008-06-19 ジョアン マクローリン， シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
JP2009511568A (ja) * 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
TW201518320A (zh) * 2007-06-12 2015-05-16 Ac Immune Sa 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
CA2714413C (fr) * 2008-02-08 2017-01-24 Immunas Pharma, Inc. Anticorps capable de se fixer specifiquement a un oligomere b et utilisation dudit anticorps
DE102008008572A1 (de) * 2008-02-11 2009-08-13 Dr. Egger Privatstiftung Trainingsgerät und Nachrüstsatz für ein solches mit Vibrationsexzenter
AU2009217518A1 (en) * 2008-02-28 2009-09-03 Merck Sharp & Dohme Corp. 2-aminoimidazole beta-secretase inhibitors for the treatment of Alzheimer's disease
AU2009242127B2 (en) * 2008-04-29 2014-03-27 Pharnext New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of cell stress response
EA024147B1 (ru) * 2008-04-29 2016-08-31 Фарнекст Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
US8865701B2 (en) * 2009-02-20 2014-10-21 Merck Sharp & Dohme Corp. Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease
US8512677B2 (en) * 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
EA032675B1 (ru) * 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
EP2462162B1 (fr) * 2009-08-06 2016-10-12 Immunas Pharma, Inc. Anticorps qui se lient spécifiquement à des oligomères bêta a et utilisation de ceux-ci
WO2012009442A2 (fr) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Anticorps monoclonal anti-addl et ses utilisations
ITVI20110005U1 (it) * 2011-01-26 2012-07-27 Atlas Filtri S R L Apparato portatile per l'estrazione rapida solido-liquido dinamica.
EP2732286A4 (fr) * 2011-07-13 2015-02-25 Merck Sharp & Dohme Procédé de détection d'oligomères bêta-amyloïdes dans un échantillon liquide et ses utilisations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体

Also Published As

Publication number Publication date
CA2891627A1 (fr) 2014-06-12
US20130089537A1 (en) 2013-04-11
WO2014089149A1 (fr) 2014-06-12
US9320793B2 (en) 2016-04-26
EP2928561A1 (fr) 2015-10-14
CA2891627C (fr) 2023-03-07
JP2016502553A (ja) 2016-01-28
EP2928561A4 (fr) 2016-08-17
JP2019023201A (ja) 2019-02-14
AU2013355359B2 (en) 2017-12-21
AU2013355359A1 (en) 2015-05-21
US20150320860A1 (en) 2015-11-12
JP6731727B2 (ja) 2020-07-29

Similar Documents

Publication Publication Date Title
WO2014089149A8 (fr) Procédé de traitement d'une maladie associée à une espèce oligomère soluble d'amyloïde bêta 1-42
WO2015197823A3 (fr) Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
WO2017106656A8 (fr) Molécules d'anticorps anti-pd-1 et leurs utilisations
WO2016207273A3 (fr) Protéines qui se lient à des antigènes multispécifiques
WO2017181098A3 (fr) Molécules d'anticorps se liant au virus zika et leurs utilisations
WO2015197598A3 (fr) Protéines multispécifiques de liaison à un antigène
HUE044416T2 (hu) Módosított, konjugált dién-bázisú polimer, eljárás elõállítására és módosított konjugált dién-bázisú polimer kompozíció
WO2015081085A3 (fr) Méthodes de traitement d'une thauopathie
WO2015112900A8 (fr) Molécules d'anticorps anti-pd-1 et leurs utilisations
WO2016033439A3 (fr) Compositions et méthodes pour le traitement d'une maladie ou d'un trouble inflammatoire
WO2014124334A3 (fr) Anticorps anti-transthyrétine et leurs utilisations
WO2017106684A3 (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
WO2014144632A8 (fr) Anticorps anti-pac1 humains
WO2016005466A3 (fr) Anticorps se liant aux protofibrilles ass améliorés
JP2016175822A5 (fr)
EP2998416A4 (fr) Tôle d'acier à module de young élevé à haute résistance, et son procédé de fabrication
WO2016005328A3 (fr) Produits immunogènes à base de séquences d'acides aminés de mutéines de la protéine ss-amyloïde (ass) et leurs utilisations
SG11202109545VA (en) Treatment employing anti-il-13r antibody or binding fragment thereof
EP2998415A4 (fr) Tôle d'acier à module de young élevé à haute résistance et son procédé de fabrication
WO2016055941A8 (fr) Anticorps anti-tau et ses utilisations
WO2019173795A3 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et méthodes de traitement de la maladie d'alzheimer
WO2015033224A3 (fr) Méthodes de traitement du syndrome de l'x fragile et de troubles associés
WO2015187521A3 (fr) Anticorps anti-blys
WO2015081073A3 (fr) Compositions et procédés pour moduler une réponse immunitaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13859810

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2891627

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013355359

Country of ref document: AU

Date of ref document: 20131204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14648316

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015545800

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2013859810

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013859810

Country of ref document: EP